spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  olanzapine 

 HSMN NewsFeed - 5 May 2020
Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams' Role Expanded To Chairman And CEO
Biopharmaceuticals Drug Delivery Neurology Personnel
 HSMN NewsFeed - 15 Jul 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 29 Aug 2018
Impel NeuroPharma Annouces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
Biopharmaceuticals Drug Delivery Neurology
 HSMN NewsFeed - 22 Jun 2018
Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine
Biopharmaceuticals Drug Delivery Neurology FDA
 HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 29 Nov 2013
New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
Biopharmaceuticals
 HSMN NewsFeed - 5 Jan 2010
Corcept Therapeutics Announces Four Anticipated Milestones for 2010
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2009
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jul 2009
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2008
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Oct 2008
Eli Lilly and Company Resolves Investigation Involving Numerous States
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2008
CHMP Recommends Approval of Olanzapine Long-acting Injection for Maintenance Treatment of Schizophrenia in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2008
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2008
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
FDA Issues Not-Approvable Letter for Lilly's Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2008
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2007
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
Biopharmaceuticals
 HSMN NewsFeed - 11 Sep 2007
Corcept Therapeutics Receives FDA Notification Opening IND for CORLUX(R) for the Treatment of Cushing's Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2007
Statement of Eli Lilly and Company on Dr. David Egilman Settlement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 9 Jul 2007
Corcept Therapeutics Receives Orphan Drug Designation for CORLUX(R) Treatment of Cushing's Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jun 2007
TransOral Pharmaceuticals, Inc. Changes Name to Transcept Pharmaceuticals, Inc.
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Eli Lilly and Company Comments on Recent Court Rulings Regarding Zyprexa(R) Patents
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 31 Mar 2007
Corcept Therapeutics Announces $9 Million Private Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Biopharmaceuticals
 HSMN NewsFeed - 28 Mar 2007
Corcept Therapeutics Announces Chief Financial Officer Resignation
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2007
Corcept Therapeutics Announces Phase 3 Study Evaluating CORLUX(R) for Psychotic Major Depression Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2007
Eli Lilly and Company Statement: Judge Grants Lilly's Request for a Permanent Injunction Involving Misleading Selection of Illegally Leaked Lilly Documents
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 26 Dec 2006
U.S. Appeals Court Upholds Lilly's 2011 Zyprexa Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 21 Dec 2006
Eli Lilly and Company Statement Regarding Today's New York Times Article - December 21, 2006
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Barr Receives Tentative Approval for a Generic Version of ZYPREXA(R) Zydis(R) Tablets, 5mg, 10mg, 15mg and 20mg
Biopharmaceuticals FDA Generics
 HSMN NewsFeed - 17 Oct 2006
Lilly Announces Acquisition of ICOS Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Sep 2006
Corcept Therapeutics Announces Negative Results From the Second of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2006
Government Approves Lilly's Medicare Part D Patient Assistance Program
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 May 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
First Head-to-Head Study Suggests Significantly Greater Symptom Improvement for Symbyax(R) Compared to Lamotrigine in Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
Corcept Therapeutics Completes Enrollment in Second Phase 3 Study for Treating Psychotic Major Depression
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 44

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 44 additional stories matching:
olanzapine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.